Last reviewed · How we verify
Ampicillin;Amoxicillin
Ampicillin and amoxicillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Ampicillin and amoxicillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Bacterial infections including otitis media, sinusitis, and respiratory tract infections, Urinary tract infections, Skin and soft tissue infections.
At a glance
| Generic name | Ampicillin;Amoxicillin |
|---|---|
| Also known as | Ampicillin Ratiopharm, Amoxicillin ratiopharm |
| Sponsor | University of Ulm |
| Drug class | Aminopenicillin (beta-lactam antibiotic) |
| Target | Penicillin-binding proteins (PBPs); bacterial peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These aminopenicillins are bactericidal agents that penetrate bacterial cell walls and irreversibly inhibit transpeptidase enzymes responsible for cross-linking peptidoglycan strands. This disruption of cell wall integrity leads to bacterial cell lysis and death. They are effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections including otitis media, sinusitis, and respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Streptococcal pharyngitis
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction/anaphylaxis
- Abdominal pain
- Vomiting
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. (PHASE3)
- Choline to Improve Malnutrition and Enhance Cognition (NA)
- Effect of Antibiotics on Enteric Neurons and Glia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ampicillin;Amoxicillin CI brief — competitive landscape report
- Ampicillin;Amoxicillin updates RSS · CI watch RSS
- University of Ulm portfolio CI